Optqc

OptQC names Tomohiro Maeda executive officer and CFO to strengthen finance for MoQuren commercialization

OptQC announced that Tomohiro Maeda will assume the role of executive officer and CFO effective August 1, 2026. Following the start of operations of Japan’s first domestic photonic quantum computer光量子コンピューター / Photonic Quantum Computer / Optical Quantum ComputerA quantum computer that performs quantum computation using photons or the quantum states of light as carriers of information.QI NotePhoton generation, loss, detection, and integration affect performance. One should consider not only the number of qubits but also loss rates and the performance of light sources and detectors., “MoQuren,” the company intends to strengthen the capital strategy, fundraising, and investor relations needed for commercialization and global expansion.

Announcement summary

Maeda has held finance-related roles at USEN, Eli Lilly Japan, Nomura Holdings, Abbott Japan, and Promesera Bioscience. He has been involved in fundraising, investor relations, M&A, and IPO preparation, and has led fundraising of more than ¥10 billion from domestic and international investors.

From June 2022 he served as CFO of PRISM BioLab and led its listing on the Tokyo Stock Exchange Growth Market in July 2024. At OptQC he will be responsible for formulating medium- to long-term financial strategies, exploring diverse financing options, and engaging with investors.

In July 2026, OptQC installed MoQuren at AIST’s G-QuAT and began operations. Going forward, the company plans to use the system for technical validation and to create use cases in areas such as drug discovery and finance.

Key points

  • Tomohiro Maeda was appointed OptQC’s executive officer and CFO effective August 1, 2026.
  • Maeda has experience in fundraising, IR, M&A, and IPO preparation, and has led fundraising exceeding ¥10 billion from domestic and foreign investors.
  • In July 2026, OptQC installed its first domestic photonic quantum computer, MoQuren, at G-QuAT and began operations.
  • The company is strengthening its financial and management foundation to support growth investments, fundraising, commercialization, and global expansion.

Technical and business significance

This appointment signals OptQC’s shift from a research-and-development focus toward a phase emphasizing system validation and commercialization, strengthening its capital policy and fundraising capabilities. Technically, the move does not announce new performance improvements, but aims to support the investments needed for validation and use-case development using MoQuren from a financial perspective. On the business side, Maeda’s experience in fundraising, IPO preparation, and investor relations will be applied to building the management foundation needed for growth investment and global rollout.

Points to watch

Key questions going forward include whether the company will disclose specific financing methods, investment scale, and timing. For MoQuren-based validation, it will be important to see what use cases and results emerge in drug discovery and financial applications. The timing of commercial service offerings, the business model, and which overseas markets OptQC targets will also be crucial indicators of the effectiveness of this strengthened financial organization.

✍️ Quantum Index Analysis

The notable point in this announcement is not simply the hiring of someone with IPO experience, but that OptQC appears to be entering a stage where technology development alone is no longer sufficient. The start of MoQuren’s operations is a milestone, but “a system is running” can mean different things for research use, external-user validation, stable operation, and commercial service. Transitioning to a business model where customers pay requires sustained funding for validation, improvement, manufacturing, talent, and international expansion.

Maeda’s background in fundraising, IR, M&A, and IPO preparation expands OptQC’s options for meeting that funding demand. However, this announcement alone does not reveal the scale or timing of additional fundraising or specific capital policies including an IPO. Rather than viewing the CFO appointment as proof of growth, it should be seen as a preemptive strengthening of financial functions in preparation for future large-scale investments.

Related articles

Source

Read the original announcement

If you found this article useful, please consider sharing it.
𝕏 Share this article

Similar Posts